Introduction
Materials and methods
Patient eligibility
Characteristic | Group A | Group B |
χ
2
|
P
|
---|---|---|---|---|
(n = 49) | (n = 49) | |||
Gender
| ||||
Male | 32 | 35 | 0.425 | 0.514 |
Female | 17 | 14 | ||
KPS
| 80.5 ± 2.13 | 81.2 ± 1.71 | 1.794* | 0.076 |
Age (years)
| ||||
Median (range) | 54 (38–71) | 52 (40–69) | 1.515* | 0.133 |
Recurrence time (months)
| ||||
Median (range) | 11.4 (6–24) | 12.2 (7–23) | 1.978* | 0.051 |
Recurrent tumor size (cm3) | 9.84 ± 3.32 | 10.23 ± 4.13 | 0.515* | 0.608 |
Anatomic recurrence (number) | 11 | 13 | 0.221 | 0.638 |
Postoperative pathological stage
| ||||
I + II | 30 | 27 | 0.377 | 0.538 |
III + IV | 19 | 22 | ||
Recurrence of locoregional lymph node metastases (number) | ||||
≤2 | 38 | 40 | 0.251 | 0.616 |
>2 | 11 | 9 |
Assessment of locoregional mediastinal recurrence
Radiotherapy and chemotherapy
Follow-up
Statistical analyses
Results
Response rates
Overall survival
1-year SR (%) | 3-year SR (%) | 5-year SR (%) | MS (Mo; 95% CI) | |
---|---|---|---|---|
Group A | 69.4 | 28.6 | 8.2 | 19 (14; 26) |
Group B | 85.7 | 46.9 | 14.3 | 35 (30; 40) |
χ
2
| 4.602 | 4.298 | 3.798 | |
P
| 0.032 | 0.038 | 0.051 |
Toxic effect of radiochemotherapy
Group | Acute toxicity ≥ grade 2 (n) | Late toxicity (n) | ||||||
---|---|---|---|---|---|---|---|---|
Esophagitis
|
Leukopenia
|
Nausea and vomiting
|
Diarrhea
|
Hepatic and renal dysfunction
|
Radiation pneumonia
|
Stomal stenosis
|
Heart injury
| |
A | 10 | 8 | 5 | 1 | 0 | 1 | 1 | 0 |
B | 22 | 15 | 14 | 3 | 2 | 4 | 3 | 2 |
χ
2
| 6.682 | 2.784 | 5.290 | |||||
P
| 0.01 | 0.010 | 0.021 | 0.358* | 0.495* | 0.362* | 0.242* | 0.495* |
Multivariate analyses for prognostic factors
β | Sx |
χ
2
|
P
| |
---|---|---|---|---|
GTV (<5 cm
3
vs. ≥5 cm
3
)
| 1.452 | 0.343 | 6.673 | 0.003 |
Postoperative T stage (I + II stage vs. advanced stage)
| 0.685 | 0.275 | 1.843 | 0.005 |
Regional recurrence of lymph node metastases (=1 vs. >1)
| 0.021 | 0.004 | 1.016 | 0.002 |
Chemotherapy (Yes vs. No)
| 1.035 | 0.395 | 6.879 | 0.009 |